IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression-Reference-Cited by-同舟云学术

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression

Published:2016-04-25 Issue:10 Volume:18 Page:1402-1412
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:NEUONC

Author:

Zhang Xiaoran,Rao Aparana,Sette Paola,Deibert Christopher,Pomerantz Alexander,Kim Wi Jin,Kohanbash Gary,Chang Yigang,Park Yongseok,Engh Johnathan,Choi Jaehyuk,Chan Timothy,Okada Hideho,Lotze Michael,Grandi Paola,Amankulor Nduka

Funder

Copeland Foundation Award

Brain Awareness 5K Award

NIH

University of Pittsburgh Clinical Scientist Training Program (CSTP) and Clinical and Translational Science Institute

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/18/10/1402/17430752/now061.pdf

Reference53 articles.

1. Developmentally regulated 75-kilodalton protein expressed in LLC-PK1 cultures is a component of the renal Na+/glucose cotransport system

2. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

3. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

4. (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

5. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A potential mechanism of tumor immune escape: Regulation and application of soluble natural killer group 2 member D ligands (Review);Oncology Reports;2024-08-14

2. Altered cancer metabolism and implications for next-generation CAR T-cell therapies;Pharmacology & Therapeutics;2024-07

3. CPI203, a BET inhibitor, down-regulates a consistent set of DNA synthesis genes across a wide array of glioblastoma lines;2024-06-30

4. Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review);Molecular and Clinical Oncology;2024-06-28

5. Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside;Pharmaceuticals;2024-05-26